STAT+: CAR-T therapies from Bristol, Gilead superior to standard treatment in blood cancer, studies show

CAR-T therapies from Bristol Myers Squibb and Gilead were superior to standard treatment in blood cancer, new results from two randomized clinical trials show.

Click to view original post